SCHEMBL2243847

SCHEMBL2243847

COc1cc(NC2=C(Cl)C(=O)c3ccccc3C2=O)ccc1S(=O)(=O)Nc1ccc(C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 7/20 0.61
MAPT P10636 5/20 0.61
RAB9A P51151 5/20 0.61
NPC1 O15118 4/20 0.61
MEN1 O00255 4/20 0.61
KMT2A Q03164 4/20 0.61
MITF O75030 2/20 0.61
SMN1; SMN2 Q16637 7/20 0.53
LMNA P02545 5/20 0.53
MAPK1 P28482 5/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
KDM4E B2RXH2 1/20 0.53
GLA P06280 1/20 0.53
POLB P06746 1/20 0.53
RECQL P46063 1/20 0.53
TP53 P04637 1/20 0.48
CDC25A P30304 1/20 0.48
CDC25B P30305 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2244992 0.91 CYP19A1 (0.55) HTTMAPTRAB9ANPC1MEN1
SCHEMBL2237410 0.90 MEN1 (0.55) HTTMAPTRAB9ANPC1MEN1
SCHEMBL2241648 0.87 MEN1 (0.50) HTTMAPTRAB9ANPC1MEN1
SCHEMBL15906856 0.83 MAPT (0.61) HTTMAPTRAB9ANPC1MEN1
SCHEMBL12283197 0.81 MAPT (0.60) HTTMAPTRAB9ANPC1MEN1
SCHEMBL12352060 0.80 MAPT (0.61) HTTMAPTRAB9ANPC1MEN1
SCHEMBL2241087 0.80 MAPT (0.76) HTTMAPTRAB9ANPC1MEN1
SCHEMBL15906855 0.78 MAPT (0.60) HTTMAPTRAB9ANPC1MEN1
SCHEMBL4868219 0.78 MAPT (1.00) HTTMAPTRAB9ANPC1MEN1
SCHEMBL12283300 0.76 MAPT (0.58) HTTMAPTRAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 US disclosed
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS PSMB7, PSMD7, PSMB6 HTT 1280/4885MAPT 4401/4885RAB9A 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.